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Protein aggregation has now become recognised as an important and generic aspect of protein energy landscapes. Since the discovery
that numerous human diseases are caused by protein aggregation, the biophysical characterisation of misfolded states and their aggre-
gation mechanisms has received increased attention. Utilising experimental techniques and computational approaches established for the
analysis of protein folding reactions has ensured rapid advances in the study of pathways leading to amyloid ﬁbrils and amyloid-related
aggregates. Here we describe recent experimental and theoretical advances in the elucidation of the conformational properties of
dynamic, heterogeneous and/or insoluble protein ensembles populated on complex, multidimensional protein energy landscapes. We dis-
cuss current understanding of aggregation mechanisms in this context and describe how the synergy between biochemical, biophysical
and cell-biological experiments are beginning to provide detailed insights into the partitioning of non-native species between protein fold-
ing and aggregation pathways.
 2007 Elsevier Inc.
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Open access under CC BY license.Despite their molecular diversity, proteins possess the
common property that, in general, they can rapidly and
spontaneously self-assemble into elaborate three-dimen-
sional structures that are required for their speciﬁc func-
tions. How this molecular feat is achieved is a
fascinating, but still unanswered, question. Since the dis-
covery that the native conformation is not the only fold
available to a polypeptide chain, but an alternative struc-
ture, known as amyloid, may represent the primordial
ground state of protein folding and assembly reactions,
research into the speciﬁc features of polypeptides that
ensure folding to the correct, functional native state and
how oﬀ-pathway species are avoided, has increased in
momentum enormously. Most importantly, the synergy
between theoretical studies, biophysical experiments, cell
biology and medicine is now beginning to provide common0003-9861 2007 Elsevier Inc.
doi:10.1016/j.abb.2007.05.015
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Open access under CC BY license.principles that rationalise the sequence-speciﬁc partitioning
of polypeptides between protein folding and aggregation,
as well as its pathological consequences.
This review describes the current molecular understand-
ing of the mechanisms of protein folding and protein aggre-
gation. We start by discussing current concepts of protein
ensembles, derived from a combination of experiment, the-
ory and simulation, in terms of kinetically meta-stable
states on the energy landscape. The properties of interme-
diate states are particularly highlighted, as these species
have been shown to be of particular importance in deter-
mining the diversion of molecules between the folding
and aggregation landscapes. We then describe recent
advances in theoretical frameworks, as well as the develop-
ment of experimental techniques that, together, are begin-
ning to reveal the structural complexity of states
populated at diﬀerent locations on the energy landscape,
as well as the kinetic pathways that link them. Subse-
quently, the intrinsic properties of the polypeptide chain
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folded proteins and the inﬂuence of extrinsic, cellular fac-
tors in shaping the landscape will be discussed, highlighting
in particular how evolution has solved the ‘protein folding
problem’ by establishing amino acid sequences that fold
into stable proteins with desired functions whilst avoiding
non-native, non-functional conformers. Finally, we con-
clude by pointing out the challenges that lie ahead in our
quest to understand protein folding energy landscapes in
atomistic detail and how we might hope to utilise this
knowledge to control the partitioning between folding
and aggregation in the future.Towards the description of protein conformational ensembles
The folding side of the protein energy landscape
The fact that protein folding must occur within a biolog-
ically feasible timescale excludes the possibility of a ran-
dom-search mechanism for protein folding [1]. Therefore,
and as a general principle, kinetic pathways lay the founda-
tion to an ordered protein folding reaction. Although the
complete folding trajectory of only very simple proteins
has been determined at atomic-level resolution to date
[2], biophysical and theoretical experiments picture protein
folding, in general, as a sequential and highly cooperative
reaction [3]. To envision the conformational space avail-
able to each individual polypeptide sequence under a given
condition, the concept of energy landscapes was introduced
[4,5]. This theoretical formalism describes the progression
of unfolded polypeptide chains along an energy landscapeFig. 1. Illustration of a combined energy landscape for protein folding and a
landscape, showing the multitude of conformational states available to a polyp
the conformational search of a single polypeptide chain to a functional mono
(dark grey). (b) Proposed pathways linking the conformational states shown intowards the compact native structure (Fig. 1). For small
proteins this landscape appears to be funnel-like and repre-
sents the evolutionary selection of polypeptide sequences
able to fold rapidly and reliably towards a unique native
state [6]. On the other hand, larger polypeptide sequences
have rougher energy landscapes, allowing the population
of partially folded species that may be on- or oﬀ-pathway
to the native fold [7,8]. Characterising the multitude of con-
formational states populated on this energy landscape is
not only crucial for developing an understanding of the
determinants of protein folding and aspects of protein
function, but it also contains crucial clues about side-reac-
tions such as protein aggregation [9,10]. Such a character-
isation involves describing the structural, kinetic and
thermodynamic properties of all conformations accessible
to a given polypeptide sequence. Obtaining this description
has proved to be immensely challenging, however, as tech-
niques able to resolve and structurally characterise these
rapidly interconverting species needed to be developed, as
well as the theoretical framework to interpret them. None-
theless, using an array of ingenious experiments and by
combining these with simulations and new theories,
detailed insights into at least the most highly populated
conformational ensembles on the protein folding landscape
and the transition state barriers that separate them have
emerged over the recent years.Unfolded states
Over the last decade enormous progress has been made
in describing the conformation of unfolded states. Theseggregation. (a) The surface illustrates the roughness of the protein energy
eptide chain. While rather simple folding funnels (light grey) can describe
mer, intermolecular protein association dramatically increases ruggedness
(a) populated on the combined folding and aggregation energy landscape.
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tein folding reactions [11], but for natively unfolded chains,
may have important roles in a variety of biological pro-
cesses [12]. While proteins unfolded with high concentra-
tions of chaotropes or at high temperature initially led to
the impression that unfolded states are random coils that
lack persistent non-random inter-residue interactions [13],
this view has changed over recent years as a result of an
increasing number of detailed studies on denatured states
under a range of solution conditions, principally using
NMR1 spectroscopy [10]. Current views consider that, even
in high concentrations of denaturant, signiﬁcant clustering
of aliphatic and aromatic side chains may persist, even if no
signiﬁcant secondary structure is retained [14,15]. Under
less harsh conditions, in which some proteins can be tricked
into being unfolded in the absence of denaturant (for exam-
ple by mutating the sequence or changing the pH), the
unfolded state has been shown to contain signiﬁcant
native-like interactions formed in concert with substantial
numbers of both native and non-native side chain contacts
[16,17]. In the case of the drk-SH3 domain a direct charac-
terisation of the unfolded state has been possible due to the
fact that the unfolded state is populated at equilibrium with
the native protein under non-denaturing conditions. Using
circular dichroism (CD), ﬂuorescence and NMR spectros-
copy, Crowhurst et al. were able to provide evidence for
cooperative interactions in this unfolded state, based on
non-native hydrophobic clusters around tryptophan resi-
dues [18]. Importantly, non-native interactions involving
aromatic clusters have also been shown to persist in high
denaturant concentrations in the case of lysozyme [14].
Fersht and coworkers have recently used a series of high-
resolution NMR experiments to picture the structure of
the denatured state of the Drosophila Engrailed Homeodo-
main (En-HD). Using the mutant protein L16A, a variant
that is unfolded under conditions in which the wild-type
sequence is native, the unfolded state was shown to be
highly structured, possessing substantial amounts of native
secondary and tertiary structure [19]. This denatured state
under physiological conditions is reminiscent of protein
folding intermediates found in other proteins [20–22] and
highlights the diﬃculty in deﬁning species as physiologi-
cally unfolded or intermediate when populated very early
in folding [23]. Single molecule spectroscopy, in particular
Fo¨rster resonance energy transfer (FRET), has been extre-
mely powerful in separating heterogeneous subpopulations
[24], thereby allowing the analysis of unfolded species even
when present as minor conformations with the native pro-1 Abbreviations used: Ab, amyloid-beta peptide; AcP, acylphosphatase;
AFM, atomic force microscopy; b2m, b2-microglobulin; HX, hydrogen
exchange; CI2, chymotrypsin inhibitor 2; CD, circular dichroism; EM,
electron microscopy; EPR, electron paramagnetic resonance; FRET,
Fo¨rster resonance energy transfer; Hsp, heat shock protein; HX, hydrogen
exchange; Im7, immunity protein 7; MD, molecular dynamics; NMR,
nuclear magnetic resonance; PUFs, partially unfolded forms; PrP, prion
protein; ssNMR, solid state NMR; SOD, superoxide dismutase; ThT,
Thioﬂavin T; TTR, transthyretin.tein [25,26]. This approach, in combination with CD and
small angle X-ray scattering (SAXS) measurements, has
indicated a dramatic collapse of unfolded structures upon
removal of denaturant and suggests that secondary struc-
ture, as well as long-range inter-residue interactions, may
form in the unfolded ensembles that initiate the folding
reaction [27,28].
Residual structure in the unfolded ensemble has not only
been suggested to reduce the conformational search during
folding, but for some proteins may also play a role in the
onset of protein aggregation of unfolded polypeptides
[29,30]. NMR studies of the denatured states of amyloido-
genic proteins have been performed for several proteins,
including lysozyme [31], b2-microglobulin (b2m) [32] and
an SH3 domain [33]. Although the acid-denatured states
of these proteins are substantially disordered and dynamic,
15N relaxation experiments indicate that these ensembles
contain substantial non-native short-range and long-range
interactions, particularly involving the clustering of
aliphatic and aromatic side chains, resulting in partially
restricted conformations containing clusters of hydropho-
bic residues [31–33]. Although the eﬀect of these hydropho-
bic clusters on amyloid formation is not fully understood,
changes in the residual structure of the unfolded state can
result in modulation of ﬁbril formation rates [30], an obser-
vation that has also been found in protein folding studies
[34]. Numerous experimental techniques [35], as well as
theoretical studies [36], have indicated that a signiﬁcant
fraction of the contacts that deﬁne the native structure of
a protein may already be present in the unfolded state,
and their presence may be required to establish the overall
native topology required for an eﬀective folding reaction
[37]. Interestingly, these structural preferences, determined
by the intrinsic properties of the amino acid sequence, e.g.
secondary structure propensity, charge and hydrophobicity,
not only determine the ability of the polypeptide chain to
fold eﬃciently to the native structure, but seem to be equally
important in determining protein aggregation kinetics (see
below). Therefore, Nature has had a diﬃcult task in evolv-
ing sequences able to fold to a functional structure whilst
avoiding oﬀ-pathway reactions that may lead to deadly
oligomeric and/or polymeric structures.
Intermediates and transition state ensembles (TSE)
The role of intermediates (i.e. populated partially folded
states) in protein folding has been a long-standing question
[8]. Based initially on the observation that many small pro-
teins fold with apparent two-state kinetics [38], folding
intermediates were initially thought to be aberrant misfolds
on the folding energy landscape that represent oﬀ-pathway
species or kinetic traps [39]. Today the increase in the
power of experimental methods has resulted in the number
of proteins folding via a pure two-state mechanism declin-
ing to only one or two remaining examples [8]. For exam-
ple, experiments capable of measuring folding events on a
ls timescale (e.g. using ultra-rapid mixing [40]), or of
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lation spectroscopy (FCS) or NMR spectroscopy [24,41])
have revealed partially folded states populated during the
folding of even the simplest proteins [42,43]. In particular
NMR relaxation dispersion measurements are highly sensi-
tive for the detection of minor populations (down to 1%) of
non-native protein conformations and can provide residue
speciﬁc information on the kinetic and thermodynamic
properties of these species [44,45]. Molecular dynamics
(MD) simulations have also predicted the presence of inter-
mediates in proteins initially characterised as two-state,
guiding subsequent protein engineering experiments to sta-
bilise such species so that they can be detected experimen-
tally [46]. The length of polypeptide chain needed to span
the structural and functional universe of proteins results
in most proteins being over 200 residues in length. Such
proteins usually possess multiple domains and, as a conse-
quence, result in rough energy landscapes [8,9]. Larger
chains have a higher tendency to collapse in aqueous solu-
tion, resulting in the formation of compact states which can
contain substantial elements of native-like structure [47,48].
Reorganisation of inter-residue contacts (including both
native and non-native interactions) in these compact states
may involve high energy barriers, leading to the transient
population of partially folded intermediate states [7]. Such
species can be productive for folding (on-pathway) [49,50]
or trapped such that the native structure cannot be reached
without substantial reorganisational events (the intermedi-
ate is oﬀ-pathway) [51,52]. While a decade ago, the pres-
ence of folding intermediates was mainly inferred from
the non-linear dependence of the folding kinetics (analysed
on a log timescale) on the concentration of denaturant, or a
burst phase (apparent missing amplitude) in the initial
spectroscopic signal, technical and methodical advances
now allow the formation of intermediates to be directly
monitored (Table 1). Using these and other techniques,
early kinetic intermediates have been shown to resemble
the molten-globule intermediates found many years ago
for several proteins under mildly denaturing conditions
[53], suggesting that these equilibrium states can be consid-
ered as stable models of transient intermediates. Baldwin,
Wright and colleagues have extensively studied the rela-
tionship between the equilibrium and kinetic folding inter-
mediates of apomyoglobin. Using CD, ﬂuorescence and
NMR spectroscopy, together with quenched-ﬂow hydro-
gen exchange (HX) and stopped-ﬂow experiments, the
kinetic and equilibrium intermediates of apomyoglobin
have been shown to possess very similar conformational
properties [21,54,55]. Similar results have achieved previ-
ously and since for RNase H [56], T4 lysozyme [57] and
Im7 [58]. Trapping transiently populated species at equilib-
rium allows their analysis using a variety of structural tech-
niques (Table 1) and thus oﬀers a powerful and general
method of determining the structures of non-native states
on the folding energy landscape.
All species on the protein energy landscape are heteroge-
neous and dynamic, with species most distant from thenative structure possessing the least ordered and thereby
the most highly dynamic conformations. Rather than being
able to deﬁne the structures of non-native states, therefore,
as can be performed classically for native proteins using
NMR or X-ray methods, non-native species are better
described as conformational ensembles. Phi-value analysis,
a pioneering protein engineering technique introduced by
Fersht and coworkers [59], has been used extensively to
picture the ensemble of conformations that make up the
transition state ensemble (TSE), whose formation is the
rate-limiting event in protein folding reactions. As long as
appropriate and carefully designed mutations are made
[60], phi-value analysis can reveal the role of individual side
chain moieties in stabilising the TSE and this technique has
now been used to determine the structural properties of a
large number of proteins [61]. The results revealed a surpris-
ing simplicity to the folding process, where the sequence of
events is determined predominantly by the topology of the
native state [62]. The very rapid and eﬃcient search to the
native state is encoded by a network of interactions between
key residues, forming a folding nucleus that establishes the
native topology in the TSE [37]. In the case of the 98-residue
protein acylphosphatase (AcP), as few as three residues are
suﬃcient to determine an eﬃcient search to the native
topology of this a/b protein [63]. Studies on the ribosomal
protein S6 have indicated the existence of speciﬁc, compet-
ing nuclei for a given protein fold, resulting in shifting
dominant folding channels upon sequence divergence [64].
Furthermore, using a statistical coupling approach which
takes the cooperative nature of amino acid interactions into
account, Ranganathan and colleagues were able to show the
importance of the speciﬁc distribution of just a few
conserved protein interactions in determining a protein fold
[65], opening the door to the design of new sequences
capable of eﬃcient folding to a functional state.
In the case of populated intermediates, experimental
measures such as phi-values, hydrogen exchange protection
factors or chemical shifts can be used to explore their con-
formational properties [66–68]. However, a direct interpre-
tation of these measurements in structural terms is
problematic since often the information is limited relative
to the all-atom description required for a full understand-
ing of their structural properties. In addition, the identity
of the contacts made that give rise to the experimental mea-
sure is often not known. To maximise the information con-
tent of these experiments, therefore, new methods are
currently being developed that combine MD simulations
with experimental measurements to reveal atomistic mod-
els of these structural ensembles [10]. Using this approach,
Vendruscolo and coworkers have revealed new insights
into structural properties of the unfolded state of D131D
[69], the intermediate state of the bacterial immunity pro-
tein Im7 [70], the rate determining transition state of AcP
[63] and the native state of chymotrypsin inhibitor 2
(CI2) [71]. Fig. 2 shows the application of MD simulations
restrained using hydrogen exchange protection factors to
deﬁne the conformational properties of the native state
Table 1
Examples of experimental approaches for characterising conformational ensembles populated on the protein energy landscape
Experiment Technique Species
Kinetic
Folding/assembly Spectroscopy (absorption, ﬂuorescence, infra-red, circular dichroism etc.) U, I, N, O, A
NMR (real time, relaxation and line-shape analysis etc.) U, I, N
Mass spectrometry U, I, N, O, A
Single molecule experiments (FRET, FCS etc.) U, I, N, A
Protein engineering (phi-value analysis* etc.) U, I, N
Speciﬁc dye binding (ANS, Thioﬂavin T etc.) U, I, N, O, A
Hydrogen–deuterium exchange* U, I, N, O, A
Turbidity and light-scattering N, O, A
Chemical cross-linking O, A
Equilibrium
Structure X-ray crystallography N
Fibre diﬀraction A
Electron paramagnetic resonance (EPR) A
Solution NMR (NMR order parameters*, residual dipolar couplings*, nuclear Overhauser eﬀects* etc.) U, I, N
Solid state NMR O, A
Cryo-electron microscopy A
Conformation Spectroscopy (see above) U, I, N, O, A
Electron and atomic force microscopy (EM and AFM) O, A
Analytical ultracentrifugation U, I, N, O
Gel permeation chromatography U, I, N, O
Calorimetry U, I, N
Dynamics NMR (relaxation measurements*, residual dipolar couplings*, spin-labelling techniques* etc.) U, I, N
Hydrogen–deuterium exchange* U, I, N, O, A
Denaturant and proteolysis stability U, I, N, O, A
The observable states are grouped into native state (N), intermediate state (I), unfolded state (U), oligomeric states (O) and amyloid ﬁbrils (A).
Experimental data from techniques marked by an asterisk might be used as restraints in molecular dynamics simulations. Adapted from [9].
Fig. 2. Application of restrained MD simulations to describe the conformational properties of dynamic ensembles. Structural ensembles of CI2
corresponding to (a) the crystal structure of the native state, (b) the native state ensemble determined from hydrogen exchange data and (c) the TSE
determined using experimental phi-values. (d) Comparison of experimental protection factors (black circles) with those back-calculated (solid lines) from
the native state ensemble shown in (b). (e) Agreement between the phi-values calculated from the TSE ensemble shown in c (black line) and experimental
phi-values (red circles). Figure adapted from [71] with permission.
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The results highlight the large equilibrium ﬂuctuations
encountered by the native structure, as well as the overallnative topology of the folding transition state [71]. Impor-
tantly, double mutant cycles have been used to test the pre-
dictions of the TSE structure determined for barnase using
T.R. Jahn, S.E. Radford / Archives of Biochemistry and Biophysics 469 (2008) 100–117 105phi-values to restrain MD simulations [72], whilst in the
case of Im7, cross-validation between the ensembles calcu-
lated using diﬀerent experimental parameters (hydrogen
exchange protection factors, NMR chemical shifts and
phi-value measurements) as restraints [70], has also vali-
dated the structures of its folding intermediate using this
approach. Advancing techniques such as FRET-measure-
ments or NMR-derived parameters (e.g. residual dipolar
couplings, paramagnetic relaxation enhancement, or relax-
ation dispersion (see Table 1)), are beginning to provide
routes capable of describing complex and heterogeneous
populations, and even oligomeric structures, in unprece-
dented detail [73], providing further experimental data that
can be used to test and reﬁne the restrained MD
procedures.
Native states
Even under highly native conditions, structured proteins
have access to a manifold of near-native conformations. It
has recently become increasingly evident that the native
structures of proteins show ﬂuctuations around the mini-
mal energy conformation that may result in the X-ray
structure [74]. Such movements are required in order to
encompass function, such as enzyme catalysis or ligand
binding, as well as site-to-site communication within the
globular protein fold or between protein subunits [75].
Wright and colleagues recently described the coupling
between functional low-energy states populated sequen-
tially in the catalytic cycle of dihydrofolate reductase
(DHFR) in exceptional detail using a series of high-resolu-
tion NMR experiments [76]. The results indicated the exis-
tence of a series of ‘precast’ low-energy states, made
sequentially available due to speciﬁc ligand binding that
preexist within the native ensemble, that play a key role
in enzyme catalysis. Similar experiments have revealed dis-
crete conformational species within the native ensemble of
signaling molecules, allosteric enzymes and membrane pro-
teins [41,77,78]. Native state hydrogen exchange has pro-
vided particularly valuable insights into the stability of
individual residues in native proteins, showing clear devia-
tions from ‘all-or-nothing’ protein unfolding dynamics and
revealing rarely populated non-native structures accessible
by conformational ﬂuctuations from the native state [68].
For example, Bai and colleagues have used measurements
of the denaturant-dependence of hydrogen exchange rates
to show that proteins undergo multiple localised unfolding
reactions in all regions of the protein structure [79]. These
ﬂuctuations give rise to ‘partially unfolded forms’ (PUFs)
which have been shown to exist even for the smallest pro-
tein domains found to date [80]. These ‘hidden intermedi-
ates’ cannot be observed using common spectroscopic
techniques in bulk kinetic experiments, as they are usually
populated after the rate-limiting transition state on the
folding trajectory. In the case of apoﬂavodoxin, a series
of studies by Bollen et al. have indicated the existence of
kinetic and equilibrium folding intermediates [81]. Impor-tantly, several of the PUFs are energetically close to the
native state, but oﬀ the folding pathway. Whether these
PUFs can be stabilised by the binding of ligands (and
therefore may represent functional species) or whether their
population increases due to point mutations, giving rise to
the population of aggregation-competent states, remains to
be shown. In the case of lysozyme, hydrogen exchange
experiments monitored using mass spectrometry have
revealed the link between dynamics in the native state
and amyloid ﬁbril formation [82]. While the point mutants
I56T and D67H do not alter the structure of the native
fold, they increase the rate of local unfolding events, result-
ing in an increase in the population of the aggregation
precursor species. Similarly, isomerisation of a single
cis-proline in b2m has been shown to tip the energy
landscape to favour aggregation over folding [83]. Detec-
tion and characterisation of rarely populated, partially
unfolded states within the native ensemble under physio-
logical conditions, therefore, will be crucial for our
understanding of the mechanisms that link folding and
aggregation energy landscapes.
The aggregation side of the protein energy landscape
Energy landscape roughness
Although the formulation of folding funnels provides a
useful description of unimolecular folding in dilute solu-
tion, the behaviour of the polypeptide chain in the living
cell, where the collision between molecules has to be con-
sidered, renders even more complexity onto the energy
landscape view of protein conformational space [9,84,85].
Here, the competition between intramolecular and inter-
molecular interactions needs to be considered, resulting
in a dramatic increase in landscape ruggedness. The sche-
matic depicted in Fig. 1 attempts to depict the true com-
plexity of the protein folding and aggregation energy
landscapes, by including the wide range of diﬀerent confor-
mational states and the multitude of pathways available to
each polypeptide chain as it circumnavigates the landscape
[9]. In the living cell the relative depth of each energy well is
not only determined by the polypeptide sequence, the tem-
perature and the solution conditions as is the case for the
folding of monomeric proteins, but is also governed by
the protein concentration (Fig. 1b). Relative to the in-
depth knowledge of the folding landscapes of simple, single
domain monomeric proteins, relatively little is understood
currently about the conformational states accessible to
polypeptide oligomers. Energy minima on the aggregation
side of the energy landscape might be poorly deﬁned, as
expected for broad ensembles of oligomeric states of simi-
lar energy that are rapidly interconverting, but could also
be highly deﬁned, as might be expected for higher order
species such as protoﬁbrils or ﬁbrils. For example, the
energy minimum of mature amyloid ﬁbrils might be deeper
and sharper than those of native monomeric proteins, as
suggested by the rigidity of the amyloid fold, as well as
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Here, however, even under the same solution conditions
a multitude of ﬁbril morphologies can be formed simulta-
neously, highlighting the complexity and multiplicity of
aggregation pathways [87,88]. As found for conformational
variants of native, functional proteins, the conformational
polymorphism common to many amyloid ﬁbrils can also
eﬀect their biological properties [89].
The complex interplay between precursor structure,
amyloid ﬁbril morphology and infectivity has been
described in depth by various groups for yeast prions
[90]. The prion strain phenomenon, i.e. prion particles
composed of the same polypeptide sequence that have dis-
tinct physiological eﬀects, has recently been associated with
conformation-dependent diﬀerences in prion structure and
growth rates [91,92]. For example, diﬀerent polymorphic,
self-propagating forms of the same Sup35 sequence have
been linked to variations in the strain phenotype, based
on the growth rate and ﬁbril stability (‘brittleness’) of amy-
loid ﬁbrils [93]. The propagation of ‘conformational mem-
ory’ during templated ﬁbril formation has also been shown
to be the cause of species barriers [94]. Furthermore, solid-
state NMR (ssNMR) experiments on Ab140 amyloid
ﬁbrils, formed either quiescent or with agitation, have
shown the propagation of conformational diﬀerences on
an atomic level in seeding experiments [95]. The cause of
these subtle, but highly signiﬁcant, conformational changes
is clearly situated in the assembly precursor states further
upstream in the aggregation landscape [9]. Detailed charac-
terisation of these species, therefore, will be crucial for
developing a biophysical understanding of these phenom-
ena. However, species populated early in the assembly reac-
tion are rarely and only transiently populated, and may be
extraordinarily heterogeneous, making their structural
characterisation a diﬃcult challenge for the years ahead.
Amyloid ﬁbril formation and protein aggregation diseases
An increasing number of human diseases has been
linked to protein aggregation and the aberrant accumula-
tion of protein deposits in diﬀerent tissues and organs
[96,97]. These pathological conditions include Alzheimer’s
and Parkinson’s diseases, type II diabetes and the spongi-
form encephalopathies that are characterised by amyloid
formation, as well as cystic ﬁbrosis, a1-antitrypsin deﬁ-
ciency and amyotrophic lateral sclerosis (ALS) that involve
less ordered aggregation. Together, these disorders are col-
lectively known as protein misfolding diseases [98]. One of
the most common groups of misfolding diseases are the
amyloidoses, which involve the aggregation of speciﬁc pro-
teins into ordered, insoluble, extra-cellular deposits [99].
These protein deposits contain ﬁbrillar protein assemblies
characterised by their speciﬁc dye-binding properties,
cross-b X-ray ﬁbre diﬀraction pattern and macroscopic
long, straight and unbranched morphology [100]. Perhaps
most importantly in the context of the energy landscape
view of the protein universe, the observation that virtuallyany protein sequence can form amyloid ﬁbrils given the
appropriate solution conditions, led to the suggestion that
the amyloid fold is the universal global free-energy mini-
mum of all polypeptide chains that may assembly by gen-
eric mechanisms governed by the physicochemical
properties of the polypeptide chain [101]. The amyloid fold,
consisting of continuous b-sheets with b-strands oriented
perpendicular to the ﬁbril long axis, is remarkable in its
commonality, stability and insolubility [100] and, as well
as posing a threat to human health, oﬀers exciting opportu-
nities for exploitation in nano-biotechnology [102].
It is now becoming evident that Nature has also utilised
the rigid-repeating structure of amyloid as productive
structural or genetic components in some organisms
[103]. Extraordinary conformational diversity is embodied
by prions (including the mammalian prion, PrP, and the
yeast/fungal prions Sup35, Ure2 and HET-s), which can
assemble into protein aggregates with functionally distinct
conformations, of which at least one is self-replicating [89].
This self-replication of conformational information enables
prions to act as genetic elements with the ability to transmit
diseases [104], to encode heritable phenotype traits [105], or
to encrypt molecular memories [106]. Kelly and colleagues
recently described the ﬁrst known functional human amy-
loid, Pmel17, which templates melanin formation in mela-
nocytes [107]. This ﬁnding demonstrates that amyloid is a
fundamental, and at least in some cases non-pathological,
protein fold, utilised by organisms from bacteria to
humans. Although some common properties that link a
speciﬁc polypeptide sequence to its aggregation behaviour
are emerging (see below), the molecular mechanisms
involved in diﬀerentiating between speciﬁc association into
functional, non-pathogenic amyloid ﬁbrils on the one
hand, and the development of clinical symptoms and dis-
ease progression upon uncontrolled protein aggregation
on the other, remain poorly understood and represent
major future challenges.
The mechanisms of protein aggregation
Initiating amyloid ﬁbril formation in vitro
The generic nature of the aggregation process has
enabled extensive studies of the transition between soluble
precursor states and insoluble amyloid ﬁbrils in vitro [108].
Here, the native conformation of globular proteins usually
must be destabilised (e.g. by the addition of denaturants,
low pH, high temperature, truncations or mutations) to
allow protein aggregation to occur on a biochemically fea-
sible timescale [109–111]. Speciﬁc protein destabilisation
results in an increased population of partially folded con-
formations, whose exposed aggregation-prone regions
enhance the probability of intermolecular interactions
(Fig. 3). Which factors cause destabilisation of the native
structure and the increase in the steady-state concentration
of partially folded conformers in vitro and in vivo is now
becoming clear for at least some proteins involved in
Fig. 3. Proposed mechanisms of protein aggregation. Amyloid ﬁbril formation for many proteins proceeds from intermediate partially folded states that
are formed via partial unfolding of the native structure or via the partial structuring of unfolded polypeptides. Ordered aggregates associate via
mechanisms such as domain swapping (ds), strand association (sa), edge-edge-association (ee) or b-strand stacking (bs). Self-association of these early
oligomeric species, possibly involving further conformational changes, then leads to the formation of amyloid ﬁbrils. The generic principles that govern
this self-association process and the structure of the ﬁnal amyloid ﬁbril may depend critically on the polypeptide sequence and the solution conditions. In
some proteins association of native-like monomers or non-speciﬁc self-association into disordered aggregates has been observed as the initial step in
amyloid assembly, in the latter route the polypeptide adopts an ordered b-sheet structure within the initially disordered aggregate before amyloid ﬁbril
formation proceeds.
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gation of which is involved in hereditary systemic amyloi-
dosis, single point mutations in the lysozyme gene are
associated with ﬁbril deposition in several tissues [112].
Two amyloidogenic variants (I56T and D67H) have been
studied in detail and shown to be signiﬁcantly less stable
than the wild-type protein and, importantly, to lack the
cooperativity of the native structure, leading to an
increased concentration of partially folded states at equilib-
rium [82,113]. The same principle, i.e. enhanced amyloid
propensity due to an increase in the concentration of a
key amyloid precursor has been shown for transthyretin
(TTR), a protein involved in familial amyloidotic neuropa-
thy. In this case, amyloidogenic TTR variants have been
shown to have a decreased tetramer stability and an
increase in the tetramer dissociation rate constant, that
together lead to an increase in amyloidogenesis [114]. How-
ever, for other proteins the full-length wild-type protein is
the aggregating sequence and, for this set of proteins in
particular, changes in the local environment or alterations
of protein concentration are crucial for the onset of amyloi-
dosis. For example in the case of b2m, the deposition of
which results in dialysis-related amyloidosis [115], a rare
partially folded conformation that is populated within
the native ensemble has been identiﬁed as a key aggrega-
tion precursor [83]. The dissociation of b2m from the stabil-
ising MHC class-I complex, together with the impairment
of renal clearance (the normal site of b2m catabolism),
leads to an up to 60-fold increase in the concentration of
this intermediate species, subsequently resulting in the
onset of aggregation and the deposition of the protein in
amyloid plaques. Partially structured folding intermediates
are believed to play a key role in ﬁbril formation by many
amyloidogenic proteins [83,116–118]. However, otherassembly mechanisms have been suggested, including
aggregation from a fully denatured state [119] or from
the native state [120] (Fig. 3). A detailed analysis of confor-
mational states populated in solution using powerful exper-
iments able to detect and analyse the most rarely populated
conformations (Table 1), therefore, is crucial for our
understanding of the molecular events involved in the initi-
ation of the amyloid cascade.
Intermolecular association pathways
Several models for amyloid ﬁbril formation have been
suggested based on monitoring ﬁbrillogenesis via micros-
copy, spectroscopic techniques and/or the binding of amy-
loid-speciﬁc dyes [121–124]. Classically, amyloid ﬁbrils are
formed in a nucleation-dependent manner, in which the
protein monomer is converted into a ﬁbrillar structure via
a transiently populated aggregation nucleus [125]. After
the rate-limiting step of nucleus formation aggregate
growth proceeds rapidly by further addition of monomers
or other assembly-competent species. Whereas the forma-
tion of the nucleus is thermodynamically unfavourable,
its subsequent elongation is highly favourable and proceeds
rapidly to the ultimate ﬁbril structure. By contrast, the
assembly of spherical oligomers and other preﬁbrillar
forms occurs with nucleation-independent kinetics, and
results in the formation of spherical particles or worm-like
ﬁbrils [122,126,127]. Here, polymerisation proceeds in the
absence of a lag-phase. In some cases, oligomeric species
have been suggested to be direct precursors of long-straight
amyloid ﬁbrils, whilst in other cases, an oﬀ-pathway role
has been proposed [126,128–130]. In the case of b2m amy-
loid ﬁbril formation, this question has be extensively stud-
ied using atomic force microscopy (AFM), mass
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A schematic state diagram of the b2m aggregation land-
scape is illustrated in Fig. 4. While the incubation of native
b2m at pH 7 does not result in ﬁbril formation in the
absence of ﬁbrillar seeds, incubating b2m at pH values close
to the pI results in the formation of amorphous aggregates,
whilst at low pH values worm-like ﬁbrils (around pH 3.6)
or long-straight ﬁbrils (around pH 2.5) are formed
[88,111]. These states represent thermodynamic ground
states on the energy landscape, whose population can be
shifted by factors such as agitation, ionic strength, protein
sequence or protein concentration [126]. Most importantly,
assembly into worm-like ﬁbrils has been shown to be
oﬀ-pathway to the formation of long-straight ﬁbrils, repre-
senting a competing reaction pathway (Fig. 4b). Using
non-covalent mass spectrometry, a continuum of
oligomeric species has been observed during the nucle-
ation-independent formation of worm-like ﬁbrils, while no
oligomers larger then tetramers are detected during the
assembly of long-straight ﬁbrils [127]. Assembly of b2m into
amyloid-like ﬁbrils at low pH, therefore, involves signiﬁcant
conformational rearrangement from the initially highly
dynamic, unfoldedmonomer at very low pH [32] to the com-
pact, stable cross-b structure of amyloid. By contrast, for-
mation of worm-like ﬁbrils occurs from a partially folded
conformer that retains signiﬁcant native-like structure
involving several of the native b-strands [131]. How theFig. 4. Pathway complexity of b2m amyloid ﬁbril formation. (a) Schematic stat
upon incubation of b2m under diﬀerent conditions. While the native protein
results in the protein unfolding to form partially folded (PF) or more highly unf
forming amyloid ﬁbrils with distinct morphological properties. Close to the pr
(WL) and classic long-straight ﬁbrils (LS) are formed at lower pH values. (b) Pr
like ﬁbrils or long-straight amyloid ﬁbrils. (c,d) AFM images of worm-like (c)
form with nucleation-independent kinetics (e), whilst the formation of long-stra
adapted from [126] with permission.molecular characteristics of the monomeric precursor state
and diﬀerent kinetic routes inﬂuence the assembly reaction
and the ultimate ﬁbril morphology are currently unknown.
However, the conceptual framework of the aggregation
versus folding landscapes and the associated state diagrams
of the assembly reaction (Fig. 4) provide a powerful frame-
work on which to derive such insights and to design small
molecules capable of inhibiting oligomer formation.
Structural insights into oligomer and protoﬁbril formation
Recent in vitro studies using electron microscopy (EM)
and AFM have identiﬁed and characterised several inter-
mediate structures populated during ﬁbril formation,
including small oligomers, membrane embedded pores,
and protoﬁbrils, the latter having a characteristic ‘beaded’
appearance [132,133]. Whether these structures form on-
pathway, or are oﬀ-pathway to ﬁbril formation, and which
of these structures are actually the toxic ones are probably
the most debated questions in this ﬁeld today [134,135]. In
the past few years, it has become evident that mature ﬁbrils
are biologically relatively inert species and that preﬁbrillar
species, in general, are the most cytotoxic species on the
energy landscape [136,137], although examples of toxicity
associated with mature ﬁbrils have also been reported
[138]. An exciting study by Stefani and coworkers ﬁrst
showed the ‘inherent toxicity’ of early aggregates usinge diagram representing the diﬀerent thermodynamic ground states observed
(N) remains monomeric even at high protein concentration, acidiﬁcation
olded forms (U). Above a critical concentration these species self-associate,
otein’s pI, amorphous aggregates (AA) are formed, while worm-like ﬁbrils
oposed model for competing pathways that lead to the formation of worm-
and long-straight ﬁbrils (d). All images are 1 lm2. (e,f) Worm-like ﬁbrils
ight ﬁbrils is nucleation-dependent and shows a clear lag-phase (f). Figure
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teins not associated with any amyloid disease, whilst the
mature amyloid ﬁbrils formed from these proteins lack tox-
icity, reinforcing the view that ﬁbrillar inclusions may serve
a protective role [139]. While oligomeric species have been
observed during ﬁbril formation in vitro for many proteins,
small oligomeric species have been isolated in vivo only
rarely, examples including Ab oligomers ranging from tri-
mers to 56mers [128,132,140], which have been suggested
to be involved in diﬀerent aspects of the disease pathogen-
esis [141].
As soluble spherical oligomers are frequently observed
during ﬁbril formation, obtaining insights into their struc-
tural characteristics represents an important challenge.
However, by contrast with mature ﬁbrils, little is known
about the molecular architecture of oligomers and protoﬁ-
brils, based on their metastable nature and diverse mor-
phologies [134]. Recent studies using hydrogen exchange
and proteolysis have indicated a less-ordered structure for
protoﬁlaments compared with mature amyloid ﬁbrils
[142,143], in agreement with their lower b-sheet content
suggested from FTIR and Thioﬂavin T (ThT) binding
studies [144]. Using a plethora of spectroscopic techniques,
Fink and coworkers were able to characterise the transient
oligomers populated during assembly of the natively-
unfolded protein, a-synuclein [144,145]. Here, early oligo-
mers were shown to have signiﬁcant b-sheet structure,
exposed hydrophobic patches and a compact, partially
folded structure. Determining the structure of oligomeric
particles in atomistic detail remains a challenge for the
future, requiring techniques able to decipher molecular
architectures within ensembles of interconverting and com-
monly heterogeneous structures.
How monomers stack within amyloid-like structures has
also been widely debated and, again, several models have
been proposed (Fig. 3). By contrast with ﬁbril formation
from unfolded polypeptides, where substantial refolding
has to occur (‘refolding model’), amyloid ﬁbril formation
from very native-like precursor states has been proposed
to be achieved by a very limited set of conformational
changes (‘gain-of-interaction models’), exposing a previ-
ously inaccessible surface to aid polymerisation [146].
Recent experimental evidence suggests that amorphous
aggregated material may initiate amyloid ﬁbril formation
from unfolded polypeptides, with conformational rear-
rangements occurring subsequently to form ordered aggre-
gate amyloid precursor states (Fig. 3) [147]. On the other
hand, Chiti and coworkers have reported native-like pre-
ﬁbrillar assemblies in the aggregation pathway of AcP
[120]. A direct stacking of native monomeric subunits has
been proposed for models of TTR amyloid ﬁbrils [148].
Recently, a generic cross-b spine model was proposed by
Eisenberg and coworkers [149]. Here, the ﬁbrils grow by
providing a short polypeptide segment that stacks together
to form the stable ﬁbril spine. The recently determined
high-resolution structures of the cross-b spines formed by
13 diﬀerent short synthetic peptides based on X-ray diﬀrac-tion of microcrystals, may envision the crystal-like packing
of such a core structure, whilst at the same time revealing
the structural diversity possible within the generic cross-b
architecture of amyloid [150]. 3D domain swapping is a
third mechanism by which monomers may stack within
amyloid ﬁbrils and their precursors. Here, homodimers
or higher-molecular weight oligomers are formed by
exchanging a speciﬁc domain, or part of a domain, between
the assembling subunits [151]. The amyloid-like ﬁbrils
formed by RNase A have been shown to form by domain
swapping in a ‘runaway’ manner [152] while retaining their
enzymatic activity in the amyloid fold [153]. Although no
single model is likely to account adequately for the proper-
ties of all amyloid ﬁbrils formed under diﬀerent conditions
and from diﬀerent polypeptide sequences, the models
described to date may guide future experiments to deter-
mine whether there is indeed a generic route to the forma-
tion of a common amyloid fold.
The amyloid ﬁbril structure
Delineating the structure, at high resolution, of an amy-
loid ﬁbril for any protein is still at the edge of our capabil-
ities, despite the fact that the ﬁrst deﬁnition of amyloid as
possessing a generic cross-b structure was made nearly 40
years ago [154]. It has been diﬃcult to obtain high-resolu-
tion structures of amyloid ﬁbrils as these species are insol-
uble and non-crystalline. However, recent advances in
experimental methods are starting to provide a detailed
picture of the amyloid architecture [100,155]. Amyloid is
deﬁned in terms of empirical observations from X-ray ﬁbre
diﬀraction, EM and speciﬁc chemical staining [99,156,157].
The cross-b ﬁbre diﬀraction pattern has two characteristic
signals, a meridional reﬂection at 4.7 A˚ along the ﬁbril axis
and a more diﬀuse equatorial reﬂection around 10 A˚ per-
pendicular to the ﬁbre direction, representing the continu-
ous b-sheet and the inter-sheet packing, respectively [158].
Variation in the models of the continuous cross-b struc-
ture, such as b-helical [159,160] or nano-tube architectures
[161], have also been suggested and are still under debate
[162]. EM and AFM studies have shown that amyloid
ﬁbrils are straight, unbranched, and about 70–120 A˚ in
diameter [163]. Furthermore, birefringence under cross
polarisers upon staining with Congo red, and a ﬂuores-
cence shift after staining with ThT, are also classical fea-
tures of the amyloid fold [157]. Although these
characteristics have been tested for ex vivo amyloid [164],
detailed information about the structure of amyloid is usu-
ally gathered from amyloid-like ﬁbrils grown in vitro, since
these lack the extraneous factors commonly associated
with amyloid ex vivo [165] and careful control of the
growth conditions in vitro can lead to much more homoge-
neous ﬁbril preparations.
Recent advances in cryoEM, ssNMR, electron para-
magnetic resonance (EPR) and X-ray crystallography are
now beginning to provide valuable, detailed, information
on the amyloid ﬁbril architecture. Using ssNMR, Ferguson
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ﬁbrils formed from a CA150-WW domain (Fig. 5a–c) [119].
In this structure, each molecule forms a pair of b-strands
stacked via speciﬁc side chain interactions, a model that
has also been proposed for the amyloid fold of the
Ab1–40 peptide [166], as well as a peptide fragment from
b2m [167]. The b-strands are packed in a parallel, in-regis-
ter manner along the ﬁbril long axis (Fig. 5a). A similar,
double b-strand-turn-b-strand motif was recently proposed
for the amyloid-like ﬁbrils of HET-s (218–289), a prion
protein domain from ﬁlamentous fungi [168]. Experimental
techniques such as hydrogen exchange, limited proteolysis,
ﬂuorescence and proline-scanning mutagenesis [143,169–
172] are important in deriving models for the ﬁbril architec-
ture, providing information including the fraction of the
polypeptide chain comprising the amyloid ﬁbril core, as
well as the speciﬁc packing of the amino acid side chains.
While these experiments provide information about local
structural order, the overall ﬁbril morphology, including
the packing of protoﬁlaments, is best described using
AFM or cryoEM. Using the latter technique, in combina-
tion with single particle analysis and helical reconstruction,
Saibil and coworkers were able to describe the 3D struc-
tures of amyloid ﬁbrils from insulin, SH3 domains and
PrP, including detailed information about the arrangement
of their protoﬁlaments [87,173,174]. In the example of
insulin (Fig. 5d–g), diﬀerent numbers of protoﬁlaments,
composed of relatively ﬂat b-sheets with a left-handed twist
(Fig. 5h), were shown to account for four diﬀerent ﬁbril
morphologies [87]. Therefore, the a-helical structure of
native insulin must reorganise substantially to form theFig. 5. General structural motifs of amyloid-like ﬁbrils. (a–c) Structural mod
view to the ﬁbril axis, indicating the continuous b-sheet hydrogen bond struct
loop-b-strand motif adopted in the amyloid structure. Structural restraints
eliminating (red) or reducing (orange) amyloid ﬁbril formation when mutated t
between strands (viewed along the ﬁbril axis as in (b)). (d–g) Surface represent
ﬁbrils contain either two (d), four (e) or six (f and g) protoﬁlaments. (h) Propos
adapted from references [119] and [87] with permission.amyloid cross-b fold. Determining how these structures
relate to those of amyloid ﬁbrils formed from more com-
plex protein structures, as well as those associated with
in vivo disease, remain signiﬁcant future challenges.
Determinants of protein aggregation
Theoretical concepts and computational models
The extreme diversity of proteins associated with amy-
loid ﬁbrils in human disease is illustrated in Fig. 6. These
structures range from natively unfolded polypeptides,
through polypeptides possessing extensive a-helical struc-
ture, to proteins containing b-sheet structure exclusively
or in part. In addition, monomeric proteins, small peptides
and proteins found naturally as multimers under physio-
logical conditions, are all known to cause human amyloid
disease (Fig. 6). The ordered aggregation of globular pro-
teins has been shown to require the partial unfolding of
the native state [108], such that a precursor state is popu-
lated that exposes aggregation-competent regions that are
usually protected against forming intermolecular interac-
tions in the native protein. Although the high-resolution
structural characterisation of amyloid precursor species
has been hindered to date because of their conformational
ﬂexibility, rarity and inherent heterogeneity, computer sim-
ulations and theoretical studies are now beginning to shed
light on the key properties of these aggregation precursor
species, as well as the molecular events in the early stages
of the assembly process, and the stability of the ﬁnal amy-
loid fold [175,176]. Importantly, these studies have revealedel for protoﬁlaments formed in vitro by a WW domain. (a) Perpendicular
ure (dotted lines). (b) Cartoon representation of the non-native b-strand-
from ssNMR measurements are indicated by arrows and side chains
o alanine are highlighted. (c) Atomistic representation of the tight packing
ation of 3D maps obtained using cryoEM for insulin ﬁbril structures. The
ed b-strand model for insulin ﬁbrils containing four protoﬁlaments. Figure
Fig. 6. Representative structures of proteins involved in disease-related amyloid ﬁbril formation. The polypeptides are coloured according to the
aggregation tendency of their amino acid sequences predicted using the algorithm TANGO [187]. Sequences shown in blue are predicted to have no
b-aggregation propensity, while polypeptide stretches coloured in yellow, orange and red indicate an increasing propensity to aggregate. Notably, the
peptide structures were obtained in the presence of ﬂuoroalcohols (calcitonin and Ab1–42) or SDS micelles (amylin), and these sequences might be
substantially less ordered in the absence of these additives. Note also that for insulin, amylin and calcitonin, the pro-peptides as well as the mature
sequences have been implicated as potentially amyloidogenic [225–227].
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tide chain play a crucial role in governing aggregation [85].
In simulations of polypeptide self-assembly the polypeptide
chains were shown to undergo a hydrophobic collapse into
partially ordered or amorphous aggregates, followed by the
transition to ordered b-sheet aggregates by optimising
intermolecular interactions [177,178]. Diﬀerent subunit
alignments have been observed, involving parallel or anti-
parallel structures and in- or out-of-register b-strands,dependent on the amino acid sequence and its length
[179,180].
The residues key to the aggregation process are thought
to be diﬀerent from those important in driving correct fold-
ing of the polypeptide chain [181], although the major driv-
ing forces (the formation of hydrogen bonds and the burial
of hydrophobic surface area) are commonly and critically
involved in both processes. Although a large part of the
polypeptide chain may be involved in the ﬁbril structure
Fig. 7. Schematic illustration of the importance of edge-strands in the
aggregation of b-sheet proteins. Local unfolding of the protective edge-
strands (orange) has been implicated in amyloid ﬁbril formation for (a)
b2m using NMR spectroscopy [83], (b) TTR using hydrogen exchange
experiments [192] and (c) SOD using protein engineering [193].
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prone to aggregation than others [183]. In fact, recent evi-
dence supports the idea that short stretches of amino acids
can trigger the aggregation of larger, normally soluble pro-
teins [184]. Thus, akin to a protein folding reaction where
only a few residues deﬁne the critical folding nucleus, but
many residues are required to support the structure of
the folding transition state [37], key residues may also be
important in governing the assembly of the polypeptide
chain into amyloid ﬁbrils. From a systematic analysis of
more than 50 mutational variants of AcP, Chiti et al.
rationalised the propensities of some sequences to aggre-
gate more rapidly than others, based simply on the physi-
cochemical characteristics of the polypeptide chain:
hydrophobicity, secondary structure propensity and charge
[185]. Combining these three parameters with further fac-
tors (e.g. peptide concentration, pH and ionic strength of
the solution) not only allows the prediction of aggregation
propensity, but also allows the prediction of aggregation
rates [186] and, therefore, provides an important step
towards a quantitative understanding of factors inﬂuencing
protein aggregation. Based on similar principles, Serrano
and coworkers have developed a generic algorithm,
TANGO, which predicts the propensity of a given, linear
amino acid sequence to form b-sheet aggregates, [187].
Although amyloid ﬁbril formation propensity is not specif-
ically predicted, the result of this algorithm is illustrated in
Fig. 6 for proteins known to aggregate into amyloid ﬁbrils
associated with human disease. Notably, aggregation-
prone stretches can be found in a-helical regions, as well
as regions forming b-sheet structures in the native protein.
In addition, regions that are either exposed or buried in the
native fold are predicted to be involved in amyloid forma-
tion, reiterating the need for partial unfolding of the native
protein during the conversion to the b-sheet structure of
amyloid. Importantly, the general success of these algo-
rithms [85,176] in predicting aggregation-prone regions in
intact proteins indicates that short stretches of the sequence
might drive the aggregation of the entire polypeptide chain
and allows rationalisation of protein aggregation behav-
iour on the basis of side-chain composition within these
speciﬁc regions. Further developments of these methods
to include the eﬀect of residual structure in unfolded states,
as well as structure in partially folded amyloidogenic inter-
mediates are now needed to quantitatively understand and
predict protein aggregation processes in vitro. Building on
these successes it may also be possible to envisage in the
future, the use of such methods to predict aggregation pro-
pensity in vivo, of immense potential importance for the
design of prospective therapies.
Intrinsic gatekeepers
Using the power of aggregation prediction algorithms,
the aggregation propensity of full proteomes has been ana-
lysed in detail [188,189]. From this study a clear evolution-
ary pressure was apparent, in which the aggregationpropensity of the sequences of functional proteins was
found to be reduced signiﬁcantly compared with random
polypeptide sequences. Although aggregation usually can-
not be completely suppressed because of the functional
and structural constraints of the native fold, aggregation
is reduced substantially by placing charged residues and/
or b-sheet breaking residues adjacent to aggregation-prone
segments [189]. Proteins thus appear to have evolved deter-
minants to prevent aggregation, while maintaining the abil-
ity to fold. For example, proline residues frequently found
in membrane a-helices are thought to maximise correct
folding by preventing misfolded (b-sheet) conformations
[190]. In addition, the edge-strands of native b-sheet pro-
teins are protected from forming intermolecular hydrogen
bonds by a number of positive design features, such as
b-bulge structures or charged residues, that protect exposed
edge-strands from improper intermolecular interactions
[191]. The importance of edge-strands in the aggregation
of b-sheet proteins under native conditions has recently been
observed experimentally. A folding intermediate, populated
in the native state ensemble of b2m under physiological
conditions, has been identiﬁed as the species involved in
amyloid ﬁbril formation and has been characterised by
NMR [83]. While retaining a native-like structure in ﬁve
of the seven b-strands of the native immunoglobulin fold,
the edge-strands A and D that cap the central core show
large structural deviations from the native conformation
(Fig. 7a), strongly suggesting that loss of these protective
features triggers aggregation. Further evidence comes from
studies on TTR [192] and SOD [193], where hydrogen
exchange and protein engineering, respectively, have indi-
cated that the edge-strands are the most labile strands of
these b-sheet proteins and that speciﬁc local unfolding of
these regions might initiate intermolecular interactions.
It has been suggested that the high conservation of pro-
line residues in the ﬁbronectin type III superfamily can be
rationalised on the grounds that these residues prevent
aggregation by interfering with the formation of b-sheet
structure [194]. A similar ‘gatekeeper’ role has recently been
proposed for glycine residues [195]. Next to being utilised as
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provide a protective mechanism, by introducing high energy
barriers on the folding energy landscape that disfavour the
unfolding of the native state and the formation of aggrega-
tion-prone partially folded species [83]. In the case of b2m,
the isomerisation of only a single, conserved proline residue
(Pro32) from the native cis-conformation into the trans-
form switches the native protein into an aggregation-prone
state. As a result of a high-unfolding barrier, this intermedi-
ate is only marginally populated in the native state ensem-
ble, and addition of copper ions or an increase in protein
concentration can shift this equilibrium towards aggregated
states [83,197]. Interestingly, a well-deﬁned ratio between
hydrophobic and polar residues has been found in all solu-
ble native proteins, with the outcome that long stretches of
alternating polar and non-polar amino acids, in general, is
avoided in native polypeptide sequences [198]. Intrinsically
unfolded proteins seem to be a good model to discover
strategies for avoiding aggregation, as they are less aggrega-
tion prone compared with compact native proteins [199].
Indeed, the amino acid propensity for being intrinsically
unfolded and the propensity for aggregation are anti-corre-
lated [85]. Interestingly, speciﬁc sequence variations have
also been discovered in multidomain proteins [200], such
as the muscle protein titin. Here, neighboring subunits show
less than 40% sequence identity, experimentally shown to be
the threshold of aggregation compatibility [201], highlight-
ing the speciﬁcity of protein aggregation [202–204]. In addi-
tion to the pressure to fold rapidly to the native state, the
suppression of oﬀ-pathway aggregation reactions has been
precisely encoded by evolution in the development of
today’s protein sequences.
Cellular protein quality control
Next to the intrinsic features of the polypeptide chain
that govern the partitioning between folding and aggrega-
tion, a battery of cellular components forms the cell’s qual-
ity-control machinery and ensures the correct folding of
proteins or the rapid degradation of mutated or misfolded
polypeptides. The folding of newly synthesised proteins to
their native conformations involves the sequential action of
multiple molecular chaperones [205]. Molecular chaper-
ones, most of which are stress inducible as heat shock pro-
teins (Hsp), act in a tightly controlled ATP-dependent
manner to bind and release unfolded or misfolded polypep-
tides [206]. Chaperones (including the Hsp100, Hsp90,
Hsp70 and Hsp60 families, for example) prevent aggrega-
tion by smoothing the energy landscape and, therefore,
decreasing the population of partially folded species
[207]. This is achieved by enhancing the rate of folding,
protecting aggregation-prone intermediates from intermo-
lecular interactions, or targeting misfolded proteins to the
degradation machinery [208]. Muchowski and coworkers
were able to show that the cellular chaperones Hsp70 and
Hsp40 attenuate the formation of spherical and annular
oligomers, whilst favouring formation of ﬁbrillar species[209], rationalising the ﬁnding that these chaperones also
suppress neurodegeneration in animal models for Hunting-
ton‘s and Parkinson’s diseases [210]. In addition to the
Hsp70 system, a study by Behrends et al. showed that the
cytosolic chaperone TRiC interferes with the aggregation
of polyglutamine proteins, driving the assembly reaction
into soluble 500–600 kDa oligomers without detectable
cytotoxicity [211]. Even through chaperones like Hsp104
can resolubilise microaggregates [212], and have been
shown to be essential for prion propagation in yeast
[213], the mechanisms for the solubilisation and degrada-
tion of large proteinaceous deposits are currently poorly
understood.
Cells use two major protein degradation systems for the
quality control of newly synthesised proteins and the dis-
posal of old or damaged proteins. As much as 30% of
the newly synthesised protein pool is degraded due to inef-
fective folding [214] via the ubiquitin–proteasome system
that removes individual proteins that have been marked
for degradation [215]. The other system, autophagy, relies
on vesicles to engulf portions of the cytoplasm and deliver
them to lysosomes. This mechanism is used to turn over
long-lived proteins and organelles [216]. A highly activated
autophagic response is observed in Huntington’s, Parkin-
son’s and Alzheimer’s diseases, presumably as a protective
response to the accumulation of toxic proteins or aggre-
gates [217]. In addition, two recent reports used autoph-
agy-gene knock-out mice to show that the lack of
autophagy is associated with progressive neurodegenera-
tion, leading to the accumulation of ubiquitin-containing
inclusion bodies, independent of the proteasome system
[218,219]. However, even for proteins that fold successfully
to their native structure and hence escape the cellular qual-
ity control machinery, random conformational ﬂuctuations
of the native protein can lead to the transient formation of
aggregation-prone intermediate states (see above). In the
crowded environment of the cell such species may have
an increased propensity to aggregate, forming small oligo-
mers or larger particles that initiate the amyloid cascade.
Especially in age-related amyloidosis this may lead to the
accumulation of large quantities of partially folded pro-
teins and the saturation of the capacity of the quality con-
trol machinery, exacerbating the formation of intracellular
aggregates before refolding or degradation is possible [220].
These examples clearly suggest that the necessity to avoid
aggregation has experienced a similar evolutionary driving
force as the pressure to fold successfully into a unique
three-dimensional structure.
Amyloid therapies
Since the identity of the toxic species for many amyloid
diseases currently remain unknown, and their structures
remain elusive, approaches for the prevention of toxicity
in amyloidosis are still in their infancy [221]. However,
attractive therapeutic approaches are based on the
idea of smoothing the protein landscape to prevent
114 T.R. Jahn, S.E. Radford / Archives of Biochemistry and Biophysics 469 (2008) 100–117accumulation of aggregation-prone or toxic species. In
vitro studies of TTR, for example, have shown that small
molecules (‘chemical chaperones’) that mimic the binding
of natural ligands and stabilise the native tetrameric struc-
ture are eﬀective anti-amyloid agents. Dobson and cowork-
ers used a single-domain fragment of a camelid antibody to
rescue the amyloidogenic lysozyme variant D67H from
amyloid ﬁbril formation [222]. Interestingly, this was
achieved by increasing protein stability and restoring the
cooperativity between the two structural domains in the
native protein, reducing the number of global unfolding
events and decreasing the probability of forming partially
unfolded states [222]. While the properties of native pro-
teins are encoded by the amino acid sequence, amyloid
deposition pathways in vivo also depend strongly on a num-
ber of cofactors including serum amyloid P (SAP) compo-
nent, apolipoprotein E and glycosaminoglycans, that
generically bind and stabilise the ﬁbrillar state [165]. In
the absence of these factors, ﬁbrils can be depolymerised,
oﬀering other routes for therapeutic intervention
[223,224]. A clear understanding of the mechanism of the
association of these cofactors with amyloid ﬁbrils may
expose further possibilities of reversing amyloid deposition,
presuming that this does not result in an increase in the
production of toxic species. Evolution has successfully
managed to avoid amyloid ﬁbril formation to an astonish-
ing degree, considering the vast amount of polypeptide
sequences crowded in vivo. However, the advances in med-
ical care that are allowing life to an increasing age are
resulting in a marked increase in protein misfolding dis-
eases in our increasingly aged population. Detailed analysis
of factors (intrinsic as well as environmental) that alter
the balance between protein folding and aggregation,
therefore, will be essential for developing future medical
interventions against these debilitating diseases.
Summary and future perspectives
Research over the last decade has provided valuable
insights into the biophysical principles of protein mis-
folding and aggregation and their relationship to human
disease. Generic principles have emerged from these stud-
ies such that detailed descriptions of both productive
folding mechanisms and the aggregation-side of the
energy landscape are beginning to emerge. Importantly,
recent studies have allowed the protein folding and
aggregation energy landscapes to be linked by deﬁning
the species that are common to both pathways. As out-
lined above, we are now able to rationalise the ﬂux
between protein folding and protein aggregation based
in part on the intrinsic characteristics of a given polypep-
tide sequence, modulated by extrinsic factors such as the
solution conditions, the binding of co-factors or cellular
stress. Furthermore, methods are now beginning to
emerge that allow detailed descriptions of diﬀerent spe-
cies on the folding and aggregation landscapes, as well
as the pathways that connect them. Although genericconcepts of protein misfolding and ﬁbril formation have
been established, the major challenge for future studies
will be in the reﬁnement and improvement of these mod-
els, so that the shape of the folding and aggregation
landscapes can be predicted under conditions relevant
to the living cell. Linking biophysical observations (e.g.
the population of oligomers and their structural proper-
ties) with the progress of disease (e.g. neuronal dysfunc-
tion and cell-death) will be a further major task. Some of
the most exciting questions for the future include: What
is the structural mechanism of aggregation initiation?
How is the stability and rigidity of amyloid ﬁbrils struc-
turally manifested? Is there a common mechanism of oli-
gomer assembly and cytotoxicity? Can we rationally
design therapies against these diseases? How has Nature
utilised the otherwise toxic amyloid fold? We still have
much to learn and there are likely to be many exciting
surprises ahead as we try to achieve better understanding
of the tight balance between protein folding and aggrega-
tion. Understanding the complex energy landscape and
determining the structural properties of rare and hetero-
geneous species populated transiently at diﬀerent stages
of folding and aggregation will undoubtedly play a sig-
niﬁcant role in this future progress.Acknowledgments
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